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Background: In 2009, China implemented the national essential medicines system by enacting the National
Essential Medicines List 2009. According to the policy of this system, primary health care institutions can only stock
and use essential medicines on the prescribed List. Meanwhile, each province can choose to make its own list of
supplemented medicines. The goal of the study is to provide suggestions for emerging problems and identify
future policy-making trends.
Methods: In this study, we statistically analyzed the National Essential Medicines List 2009 and lists of
supplemented medicines of all 29 provinces. We also examined the rationality of such medicines based on the
DELPHI method and literature review, after which we studied the provincial supplements in relation to the national
essential medicines system.
Results: We demonstrated that the National Essential Medicines List 2009 provides a comprehensive coverage of
diseases as well as reasonable varieties of drugs for their treatment. The average number of supplemented
medicines in 29 provinces is 207, with each medicine included in 2.9 provincial lists on average. Only 2.6%
supplemented medicines are included by more than half of the provinces (>15), indicating great regional variance.
Among the 32 most frequently supplemented medicines, only 18 meet the selection principles, including two with
strict usage restrictions.
Conclusion: The structure and selection of the National Essential Medicines List 2009 are relatively reasonable.
The main problems, however, include the excessive and non-scientific selection of medicines on the supplemented
medicines list. The function of the provincial lists of supplemented medicines has not been achieved, which has
influenced the effectiveness of the national essential medicines system in China.
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Currently, 160 countries have formal essential medicines
lists. More than 90% of the low- and mid-income countries
have such lists, while the percentage for high-income
countries has reached 60% [1,2]. The first edition of the
Chinese Essential Medicines List, published in 1982, did
not initially include Chinese traditional medicine [3]. In
1996, the List was revised to include both Western and
Chinese traditional medicine. From then on, the List has* Correspondence: xpzhang602@163.com
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reproduction in any medium, provided the orbeen revised once every two years. In 2004, it included
2,033 essential medicines for the treatment of most
common diseases, with 733 western drugs and 1260
Chinese traditional medicines. However, since the se-
lection was excessive and only a few policies on es-
sential medicines were in place, the lists did not play
a significant role. Due to the fact that primary health
care institutions were making profits from reselling
medicines [4] and because of the widespread abuse of
antibiotics and excessive use of parenteral [5-8],
China published the National Essential Medicines List
2009 (the 7th edition of the series), which marked the
implementation of a national essential medicines system. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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aims to (1) improve medicine availability, affordability
and safety [9-11], and (2) cut the profit link between
health institutions, doctors, and medicine (Table 1).
The essential medicines list is one of the core contents
of the essential medicines system. The system requires
that all government-run primary health care institutions
be equipped with essential medicines merely, including
those found on the National Essential Medicines List
2009 and on the respective lists of each province. This
requirement restricts the medication made available in
primary health care institutions, thus promote the
rational use of medicines and reducing the opportunities
for doctors to intentionally prescribe high-profit medi-
cines. Such requirements, therefore, highlight the
importance of scientifically selecting essential medicines
because selection directly affects the treatment results.
This study mainly focuses on two key areas of the
national medicine policy, namely, list making and policy
implementation. Based on the National Essential Medi-
cines List 2009 and the respective lists of supplemented
medicines in the provinces, this study analyzes the list-
making process and the policy optimization. In addition,
we provide suggestions on how to better implement
the essential medicines system in China and improve
the use of such essential medicines. This study also pro-
vides references on policies and approaches for other
countries that can guide the creation of essential medi-




Since 2009, China has reconstructed the National Essen-
tial Medicines List, issued supporting policies, granted
manufacturing licenses, and enacted requirements to
guide the use of such essential medicines. The innovative
measures related to the national essential medicines
practice in China are worth analyzing and discussing.
The information generated can then provide a reference
for other countries in similar situations.
Data collection and analysis
This study analyzed the National Essential Medicines
List 2009 and all other lists from 29 provinces. The data
used in the manuscript were gathered from the Internet.
Using statistical calculation and canonical analysis, weTable 1 Number of medicines included in previous national e
Edition 1982 1996 1
Western medicine 278 699 7
Chinese traditional medicine 0 1699 1
Total 278 2398 2evaluated the rationality of the structure and category of
the selected medicines at the theoretical level.
The statistical analysis included three indicators.
(1) The first is the number of medicines, which included
two parts, i.e., the average number of the supplemented
medicine by provinces and the number of each category
of medicine on the National Essential Medicines List
and on the lists of supplemented medicines based on
their effects. (2) The second indicator is the frequency of
the same medicine appearing on different supplemented
lists, which indicates the frequency of supplementation
of one category of medicine. For example, if one cat-
egory of medicine is supplemented by one province, its
frequency of supplementation is “1.” If it is included by
two provinces, its frequency of supplementation is “2.”
(3) The third indicator is the co-selection rate, which is
the quotient of the total number of supplemented medi-
cines from 29 provinces and the number of unique med-
icines on such lists. This means how many provinces on
average every supplemented medicine was selected by.
This study focuses on the rationality of the structure
and category of selected medicines from the National
Essential Medicines List as well as the supplemented
medicines using the DELPHI method and literature
review. Delphi method provides a credible and scientific
way to answer certain questions. Experts do not know
each other and they answer questions in back-to-back
style to ensure the impartiality of the results. The con-
tents of the questionnaire are designed to evaluate each
drug on the list. The experts included five long-time
pharmacy experts and five senior general practitioners.
Two rounds of questionnaire surveys were conducted.
Each expert is expected to give their opinion as to
“whether (or not) the drug meets the supplementation
criteria” and “supporting evidence.” As for the rationality
of the selected medicines category, the analysis was
made using 205 categories of Western medicine and
32 most frequently supplemented medicines by 29 pro-
vinces (frequency ≥ 16). This analysis was based on four
indicators: (1) primary clinical necessity, (2) clinical ef-
fectiveness, (3) adverse effect, and (4) competitive price.
The rationality and necessity of each category were eval-
uated according to the results of all four indicators based
on the survey from the experts. As for the structure of
the lists, a survey was conducted on whether or not the
National Essential Medicines List and the supplemented
medicines had comprehensive coverage and a reasonablessential medicines lists [12]
998 2000 2002 2004 2009
40 770 759 773 205
333 1249 1242 1260 102
073 2019 2001 2033 307
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category. The results from the first round of surveys
were listed as references for experts for the second
round. After two rounds, all experts reached a consensus
on each category.
Meanwhile, face-to-face interviews with five medicine
policy-making experts were conducted. We used a semi-
construction interview on the process of selecting the
supplemented medicines in every province, the policy
evidence of the current essential medicines system and
the emerging problems and solutions.
Based on results of the analysis, we assessed the prac-
ticality and logicality of the policies and measures of the
essential medicines system of China. We also provided
analyses and suggestions on the emerging problems in
the future.
Results
The National Essential Medicines List 2009
Rationality of the list structure
The National Essential Medicines List 2009 includes 307
medicines comprising 205 chemical medicines covering
24 categories of diseases and 102 Chinese traditional
medicine covering six categories of clinical indications.
A large proportion of the medicines are used to treat
diseases with high prevalence in China, such as diseases
of the respiratory, cardiovascular, and digestive systems.
Some chronic diseases that have rapidly spread recently,
such as hypertension and diabetes mellitus, are also cov-
ered, along with common illnesses such as cold. The
comparatively comprehensive structure and categories
of the essential medicines list meet the basic medical
needs in China.
However, we found a few problems. Several categories
of medicines are missing in the structure. First, although
there are medicines to treat certain symptoms of com-
mon diseases (e.g., cold, fever, abdominal pain, and
diarrhea), there are not enough common compound pre-
parations to provide comprehensive relief. Second, medi-
cines for chronic diseases (e.g., cardiovascular and
nervous system diseases) are also lacking. Third, some
primary health care institutions provide specialty services
that require medicines for dermatology, orthopedics,
gynecology, and so on. There are only 5 dermatology
drugs on the National Essential Drugs List, a mere 1.63%
of the entire list consisting of 307 varieties. The pro-
vinces added as many as 47 such products to their lists,
representing 2.96% of the total. There are only 8 ortho-
pedic medicines on the list, accounting for 2.6% of the
total, while the provinces added up to 70 such products,
accounting for 4.4% of supplemented total. These figures
indicate that the categories in the National Essential
Drugs List cannot meet the specific service needs of pri-
mary health care institutions. The same is true forgynecological medicine, three of which appear on the
National Essential Drugs List. Finally, medicines for chil-
dren as well as information on the appropriate dosages
are also insufficient. Few options exist in China in terms
of pediatric drugs and dosage forms, and the list of es-
sential medicines for children has yet to be introduced
[13-15]. In fact, there are only 60 medicines and dos-
age forms available for pediatric use among more than
3000 varieties of pharmaceutical preparations in China,
representing less than 2% of the total [16].
Rationality of the selected categories
In this aspect, experts questioned the safety and ration-
ality of pethidine and colchicines. The metabolite of
pethidine is norpethidine, which has a long half-life
in vivo, and can lead to mental disorders, tremors, or
convulsions because of its toxicity. Thus, its cost ef-
fectiveness is lower than other medicines in the same
category, such as morphine and diazepam. Colchicine
can cause clinical adverse events, including stoma-
chache, diarrhea, vomiting, anorexia and other gastro-
intestinal reactions, with an incidence rate of 80%.
The rest of the medicines can meet the requirements
of “safety, necessity, effectiveness, and competitive
price.”
Lists of supplemented medicines of 29 provinces
Rationality of the list structure
The supplemented lists from 29 provinces include 2062
medicines that comprise 783 chemical medicines and
805 Chinese traditional medicines, with an average of
207 per province. The lists also include 352 traditional
Tibetan medicines in Tibet and Qinghai Province, and
122 Mongolian medicines in Inner Mongolia.
The supplemented medicines cover all the categories
found on the National Essential Medicines List as well
as a new category for antineoplastic medicines. Medi-
cines for the digestive system and for the cardiovascular
system, as well as those for antimicrobial, antipyretic,
analgesic anti-inflammatory, and anti-rheumatic pur-
poses account for 42.7% of the supplemented chemical
medicines in the List. A similar trend is also present in
Chinese traditional medicines. The abovementioned
structure makes up for the deficiency of the National
Essential Medicines List (Table 2).
Rationality of the selected categories
On average, each medicine is included by only 2.9 pro-
vincial lists, indicating a rather low co-selection rate.
Based on the analysis, among the 2064 supplemented
medicines, only 41 are listed by more than half of
the provinces (> 15). These 41 supplemented medicines
include 32 chemical medicines and 9 Chinese traditional
medicines that account for just 2.6% of the total. Of the
Table 2 Distribution of medicines in the national essential medicines list and in the supplemented medicines lists (all
the supplemented medicines by 29 provinces)




C1 Antimicrobial medicine 33 95
C2 Antiparasitic medicine 7 7
C3 Narcotic 4 15
C4 Antipyretic and analgesic anti-inflammatory and anti-rheumatic medicine 9 77
C5 Medicine for nervous system 14 48
C6 Medicine for mental disorder 6 21
C7 Medicine for cardiovascular system 29 66
C8 Medicine for respiratory system 7 34
C9 Medicine for digestive system 17 96
C10 Medicine for urinary system 5 13
C11 Medicine for hematologic system 10 45
C12 Hormone and medicine affecting the endocrine system 15 50
C13 Anti-allergy medicine 4 5
C14 Medicine for immune system 2 14
C15 Vitamin, mineral substance medicine 7 34
C16 Medicine for humoral regulation 8 10
C17 Antidote 5 16
C18 Biological product 4 8
C19 Diagnostic agent 2 10
C20 Medicine for dermatology 5 47
C21 Medicine for ophthalmology 5 24
C22 Medicine for otorhinolaryngology 3 9
C23 Medicine for gynecology 3 9
C24 Medicine for birth control 1 5
C25 Antineoplastic medicine 0 25
T1 Internal medicine (diaphoresis, clearing heat, and relieving cough) 24 212
T2 Internal medicine (cardiovascular system) 16 153
T3 Internal medicine (digestive system) 20 121
T4 Internal medicine (other) 13 94
T5 Surgery 7 32
T6 Gynecology 8 62
T7 Ophthalmology 2 9
T8 Otorhinolaryngology 4 38
T9 Orthopedics and Traumatology 8 70
T10 Dermatology 0 14
Total 307 1588
Note: A kind of medicine for multi-diseases is counted only once.
C = Chemical medicines, T = Chinese traditional medicine.
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mented list, whereas 588 appear on less than five lists,
accounting for 75% of the total. Of the 805 Chinese
traditional medicines, 428 appear on only one supple-
mented list, whereas 712 appear on less than five lists,accounting for 91% of the total. The rates clearly show
that the categories of medicine in each province differ
greatly and follow no rules.
In terms of the rationality of the medicine selection,
we analyzed 32 of the most frequently supplemented
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effectiveness, adverse effect, and competitive price” using
the DELPHI method and literature review. Only 18 sup-
plemented medicines meet the selection criteria, includ-
ing 2 with strict usage restrictions (Table 3).
Several publications have reported adverse events
of certain supplemented medicines. Some drugs with ser-
ious adverse events are eliminated products from other
countries. These unsafe medicines can harm the health
of an individual when listed as essential medicines.
Discussion
Main problems of the National Essential Medicines List
and the lists of supplemented medicines implemented
in each province
Overall, the National Essential Medicines List is scien-
tific and reasonable. Despite a few problems, it has
played a positive role in guaranteeing the availability of
essential medicines, regulating medical services, and
promoting rational medication. One study from Peking
University showed that the available rate of a commonly
used drug does not exceed 40% before the system
is implemented; however, after the initial implementa-
tion at 20 provinces, they found that the availability
rate increased to about 60% after conducting a survey
between February-March 2010 [17]. Statistical data from
State Council Medical Reform Office indicated that the
average price at primary health care institutions dropped
by 16.9%. Expense of single prescription and the prescrip-
tion rate of antibiotics decreased by 9.0% and 1.38% after
the reform in township hospitals, respectively.
The provincial lists of supplemented medicines have
problems in terms of number, structure, and category of
medicine. First, the selection is excessive and does not
follow strict selection principles. The average number of
supplemented medicines in each province equals to 67%
of the entire List; such excessiveness weakens the func-
tion of the National Essential Medicines List. Second,
some categories of supplemented medicines are not
selected scientifically; thus, these lists of supplemented
medicines show characteristics of “excessiveness, disper-
sion, and disorder.” Many clinically non-preferred medi-
cines with serious side effects are introduced into
primary care health institutions due to the unscientific
selection approach. For example, somiton is the only
medicine listed by all 29 provinces. The aminopyrine
found in somiton causes hypoleukocytosis, which
resulted in 1,981 deaths in the U.S. from 1931 to 1934,
prompting the U.S. government to eliminate it from the
legal medicines list in 1938. Another ingredient of somi-
ton is phenacetin, which has been proven to be one of
the causes of renal failure and is already restricted in
many countries [18,19]. Meanwhile, cimitidine is listed
by 24 provinces and ranks second in supplementingfrequency; this has complicated pharmacological effects
and multiple side effects. It can also accentuate the
pharmacological activity or toxicity of other medicines
through drug-drug interactions. Therefore, cimitidine is
usually replaced with ranitidine [20,21]. Diethylstilbestrol
is listed by 18 provinces as a supplemented medicine for
estrogen supplement. However, it can cause serious ad-
verse events, including carcinoma of the vagina in young
girls. Such major adverse events have made diethylstil-
bestrol an uncommon choice in large hospitals both at
home and abroad [22].
Form the literature and interview date, almost all of
the 29 provinces based their selections on various
experts’ opinions in producing their respective lists of
supplemented medicines, and a majority of experts are
from the prime health care institutions. In comparison,
the selection of the WHO Lists of Essential Medicines
is mainly based on evidence-based medicine and phar-
maceutical economics – opinions of experts are only
considered as references. Currently, only a few provinces
(e.g., Sichuan) apply the method of evidence-based
medicine selection and consider the disease status in
common patients.
The function of the provincial lists of supplemented
medicines and their actual effects
Under the regulation of the essential medicines policy in
China, and due to the concern that the National Essen-
tial Medicines List may not meet all the needs of pri-
mary health care institutions, the policy now allows
province to add to the List those drugs that are asso-
ciated with current use at the first stage of the reform.
Provincial supplemented medicines should be limited to
local use for special diseases, and their usage must coin-
cide with the functions and positions of primary health
care institutions. Aims of the provincial supplementing
policy are include meeting the rational needs of prime
health care institutions, and cutting the financial ties
between doctors and drug manufacturers, gradually
changing the medication practices of doctors, promoting
the rational use of medicine, that same to essential med-
icines system.
However, the goal of this policy has not yet been
achieved. On one hand, even with regulation and revi-
sions of the principles and methods of supplementation,
the provincial supplemented lists are still unreasonable
and random. This is because the provinces have been
creating their own lists based on the existing medication
practices of their respective health care institutions and
doctors. Moreover, most provinces do not have a guide-
line on the proportion of the supplemented medicines.
These greatly have reduced the effectiveness of the
essential medicines system in promoting the rational use
of medicine and changing the medication practices of
Table 3 Analysis of the frequently supplemented chemical medicines
No. Name Frequency Suggestion Evidence
1 Colloidal Bismuth Pectin 16 Supplement Meets the selection principles
2 Gliclazide 16 Supplement Meets the selection principles
3 Chymotrypsin 17 Supplement Meets the selection principles
4 Amlodipine 17 Supplement Meets the selection principles
5 Cefaclor 17 Supplement Meets the selection principles
6 Calamine 17 Supplement Meets the selection principles
7 Morphine 18 Supplement Meets the selection principles
8 Loratadine 20 Supplement Meets the selection principles
9 Triamcinolone acetonide 20 Supplement Meets the selection principles
10 Acarbose 20 Supplement Meets the selection principles
11 Vitamin B complex 20 Supplement Meets the selection principles
12 Cefotaxime 20 Supplement Meets the selection principles
13 Tinidazole 22 Supplement Meets the selection principles
14 Etamsylate 22 Supplement Meets the selection principles
15 Flunarizine 24 Supplement Meets the selection principles
16 Cefradine 24 Supplement Meets the selection principles
17 Clotrimazole 24 Supplement external preparation only Have significant side effects by oral administration,
while effective as external anti-fungal medicine
18 Fluocinolone acetonide 17 Supplement external preparation only Have significant side effects by oral administration,
while effective as external anti-inflammatory medicine
19 Somidon 29 Cannot supplement Have significant side effects
20 Cimitidine 24 Cannot supplement Have significant side effects
21 Diethylstilbestrol 18 Cannot supplement Have significant side effects
22 Ofloxacin 16 Not supplement Levofloxacin, the levorotatory form of ofloxaxin,
is included in the essential medicines list; it is more
effective and less expensive.
23 Ambroxol 16 Not supplement Oral dosage of ambroxol is included in the essential
medicines list. The injection only applies for
emergencies, and it is more expensive.
24 Coenzyme A 16 Not supplement Mainly used for leucopenia and functional hypothermia.
Disputes exist on its effect.
25 Vitamin C 16 Not supplement Injection is included in the essential medicines list.
The oral dosage is OTC medicine; therefore, it is not
suggested to be supplemented.
26 Piracetam 17 Not supplement No sufficient clinical- or evidence-based medical
evidence to prove its effectiveness
27 Troxerutin 18 Not supplement No sufficient clinical- or evidence-based medical
evidence to prove its effectiveness
28 Lincomycin 19 Not supplement Similar effect with clindamycin in the essential
medicines list, and no clinical advantage
29 Oryzanol 21 Not supplement No sufficient clinical- or evidence-based medical
evidence to prove its effectiveness
30 Furazolidone 22 Not supplement No sufficient clinical- or evidence-based medical
evidence to prove its effectiveness
31 Roxithromycin 22 Not supplement Same antibacterial spectrum with erythromycin in
the essential medicines list; more expensive
32 Inosine 24 Not supplement No sufficient clinical- or evidence-based medical
evidence to prove its effectiveness
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cines makes it impossible to cut the financial ties
between doctors and drug manufacturers. In turn, this
makes it more difficult to meet the goal of the essential
medicines system.
On the other hand, even after the provinces added
essential drugs, the primary health care sector still
cannot meet the actual needs of doctors and patients
[23,24]. The total number of medicines available is still
high despite the fact that the List lacks some commonly
used drugs that vary in diverse regions, at various insti-
tutions, and with some doctors.
Although provincial lists of supplemented medicines
are unable to reach their original targets, revising the
National Essential Medicines List should be based on
the supplementing experience of each province; further-
more, frequently supplemented medicines with clear
pharmacological benefits should be added. After revis-
ing, the List should meet the most basic medication
needs of primary health care institutions in terms of
both the category and the number of the medicines.
Recommendations on usage policy of essential medicines
The usage policy of essential medicines is one of the key
measures of the essential medicine system in China. The
provincial supplementing policy is based on usage policy,
which is related to the selection and function of National
Essential Medicine List and the provincial lists of supple-
mented medicines. Thus, it is necessary to discuss the
current usage policy, despite the fact that it does not dir-
ectly follow from the data in research results. The usage
policy of essential medicines should also be adjusted.
Doctors in primary health care institutions should not
be limited to prescribing only the essential medicines
and should enjoy some autonomous rights within a
certain range.
A country that controls the prescription practices of
doctors with an essential medicines list covering a few
medicine categories, in order to reduce medicine cost
and promote rational medication is rare. This rarity is
due to the specificity of the medical industry and the
individual variations within it. The existence of a reason-
able enough list that suggests the best treatment therapy
for every patient is impossible because of the limitation
of categories and the number of essential medicines.
Apart from the fact that medication needs in different
areas are not the same, the limitation resulting from the
essential medicines list is in conflict with the current
medical insurance system in China, given that the list
just covers less than 1/7 of the Basic Medical Insurance
Directory. Limiting the medication of all health care
institutions and doctors to the same list of medicines
can be a short-term measure, but such a policy is inap-
propriate for the situation in China and incompatiblewith the law of medicine as a whole. This practice can
also cause conflicts between the prescription practice of
doctors and the medical needs of patients, resulting in
great decrease of doctors’ enthusiasm and patients’ satis-
faction. In fact, these events have happened in some
areas in China.
Analyzing the issue from another angle, the aim of
designing the usage policy is improving rational use and
cutting the profit link between health institutions,
doctors, and medicine. However, there are many factors
in China that cause irrational drug use. These factors
mainly include the following: (1) medical personnel
do not have the required level of knowledge and capa-
bility and may even have poor prescription habits;
(2) financial interests among pharmaceutical firms, hos-
pitals and doctors (i.e., hospitals profit by reselling
drugs); (3) patients demand inappropriate use of medi-
cines due to their limited medical knowledge and long-
term doctor-induced habits. When many patients do not
obtain the desirable outcomes, they often demand the
use of antibiotics and parenteral. Current usage policy
may not improve rational use.
As for the issue of cutting the financial ties between
doctors and drug manufacturers and then solving the
problem of the health care system, simply depending on
the essential medicines system is not enough–more compre-
hensive efforts are needed. First, the management mechanism,
compensation model, and income distribution mechanism
in health institutions should be transformed. Second, rele-
vant departments should strengthen the supervision on the
diagnosis and treatment behavior of health institutions and
health workers. Third, the production and circulation of
medicines should be regulated, including the restriction of
medicine approval, control of medicine prices, and circula-
tion cost. Finally, the mode of medical insurance payment
should be turned from post payment to the imprest
system. The current usage policy cannot obtain its goal
and would only be able to do so with the above combined
efforts.
Conclusion
The National Essential Medicines List 2009 is fairly rea-
sonable in terms of the number and structure of medi-
cine. However, the lists of supplemented medicines by
each province are excessive and are not so rational.
These lists have been created selected based on the
existing practices of local health institutions and doctors,
and such selection process prevents he essential medi-
cines system from promoting the rational use of medi-
cine and ensuring the availability and affordability of
essential medicines and drug safety. China will revise
the National Essential Medicines List in 2012. The new
selection and correlative policy should learn from the
provincial experience.
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